Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

NGNE

Neurogene Inc

Nov 21 • 04:00PM ET

20.06

-0.34 -1.67 %

Healthcare • Biotechnology • USA • NASD

Peers: NBIX RARE BLUE PRTA PTCT AXSM ACAD BTAI FATE RNA

| Held by: VTI IWM VXF IBB IWN VTWO FESM VFMO IWC AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.43	Insider Own	14.93%	Shs Outstand	14.78M	Perf Week	-11.90%
Market Cap	310.72M	Forward P/E	-	EPS next Y	-5.12	Insider Trans	0.00%	Shs Float	13.18M	Perf Month	-30.13%
Enterprise Value	55.52M	PEG	-	EPS next Q	-1.18	Inst Own	88.12%	Short Float	21.58%	Perf Quarter	0.40%
Income	-85.13M	P/S	-	EPS this Y	-1.36%	Inst Trans	6.28%	Short Ratio	13.07	Perf Half Y	16.09%
Sales	0.00M	P/B	1.12	EPS next Y	-17.94%	ROA	-37.67%	Short Interest	2.84M	Perf YTD	-12.25%
Book/sh	17.97	P/C	1.17	EPS next 5Y	-11.90%	ROE	-42.25%	52W High	37.27 -46.17%	Perf Year	16.42%
Cash/sh	17.13	P/FCF	-	EPS past 3/5Y	-57.13% -10.74%	ROIC	-31.22%	52W Low	6.88 191.78%	Perf 3Y	149.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.53% 11.44%	Perf 5Y	-91.78%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	1.47%	Oper. Margin	-	ATR (14)	2.95	Perf 10Y	-92.19%
Dividend Ex-Date	-	Quick Ratio	18.37	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	34.19	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	18.37	EPS Q/Q	17.00%	SMA20	-27.31%	Beta	1.75	Target Price	59.00
Payout	-	Debt/Eq	0.04	Sales Q/Q	-	SMA50	-21.18%	Rel Volume	0.87	Prev Close	20.40
Employees	107	LT Debt/Eq	0.03	Earnings	Nov 13 AMC	SMA200	2.32%	Avg Volume	217.62K	Price	20.06
IPO	Mar 07, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	20.76% -	Trades		Volume	188,546	Change	-1.67%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-25	Initiated	Craig Hallum	Buy	$50
May-16-25	Downgrade	Robert W. Baird	Outperform → Neutral	$24
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$65
Jun-11-24	Initiated	Robert W. Baird	Outperform	$54
Apr-29-24	Initiated	Leerink Partners	Outperform	$46
Mar-21-24	Initiated	William Blair	Outperform	$61
Jan-08-24	Initiated	H.C. Wainwright	Buy	$45
Jan-05-24	Initiated	Stifel	Buy	$31
Jan-04-24	Initiated	TD Cowen	Outperform

Nov-13-25 05:21PM	Neurogene: Q3 Earnings Snapshot (Associated Press Finance) -14.77% -14.04%
05:10PM	Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates (Business Wire)
Nov-12-25 04:01PM	Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome (Business Wire)
Nov-06-25 07:30AM	Neurogene Announces First Participant Dosed in Embolden Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome (Business Wire)
Nov-05-25 04:01PM	Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -12.83%
07:00AM	Loading…
Oct-09-25 07:00AM	Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden Registrational Trial in Q4 2025 (Business Wire) +22.18%
Oct-08-25 07:30AM	Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference (Business Wire) +10.06%
Oct-03-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.48%
Sep-05-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-20-25 11:02AM	Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed. (Barrons.com)
Aug-11-25 05:55PM	Neurogene: Q2 Earnings Snapshot (Associated Press Finance) -5.55%
04:10PM	Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates (Business Wire)
Aug-08-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-03-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-30-25 04:01PM	Neurogene Announces Registrational Trial Design for Embolden Study of NGN-401 Gene Therapy for Rett Syndrome (Business Wire) -7.49% +28.36%
09:16AM	Loading…
Jun-18-25 09:16AM	Craig-Hallum bullish on Neurogene, initiates with a Buy (TipRanks)
Jun-06-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.80%
May-26-25 11:15AM	Short Report: Bears bite into Krispy Kreme after another weak earnings report (TipRanks)
May-16-25 07:00AM	Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV (Business Wire) -7.12%
May-09-25 07:30AM	Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates (Business Wire)
May-08-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.23%
Apr-28-25 05:00PM	Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting (Business Wire) -5.91% -10.14%
Apr-02-25 04:01PM	Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome (Business Wire) +8.34% -7.55%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -17.55%
Mar-24-25 04:10PM	Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates (Business Wire)
Feb-24-25 07:30AM	Neurogene to Participate in Upcoming Conferences (Business Wire)
Nov-18-24 05:25PM	Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire) -42.58% -13.07%
04:14PM	How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week (Investor's Business Daily)
09:48AM	Neurogene Down 36% Extends Losses After Side Effect Derails Its Rett Syndrome Drug (Investor's Business Daily)
06:45AM	Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome (Business Wire)
04:10PM	Loading…
Nov-12-24 04:10PM	Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal (Investor's Business Daily) -44.08%
10:18AM	Top 1% Biotech Neurogene Crashes, Wiping Out A Run, On A Serious Side Effect (Investor's Business Daily)
06:58AM	Neurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial Data (GuruFocus.com)
Nov-11-24 04:01PM	Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome (Business Wire)
Nov-05-24 07:54AM	Neurogene Secures $200M for Genetic Therapy Development (TipRanks)
Nov-04-24 07:30AM	Neurogene Announces Oversubscribed $200 Million Private Placement (Business Wire) +43.26%
Oct-21-24 07:30AM	Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome (Business Wire)
Aug-09-24 02:52PM	NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024 (InvestorPlace)
07:30AM	Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire)
Aug-07-24 07:30AM	Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome (Business Wire)
Jul-02-24 07:30AM	Neurogene to Participate in BMO Genetic Medicines Summit (Business Wire) -5.32%
Jul-01-24 07:30AM	Neurogene Announces Addition to Russell 3000 Index (Business Wire) +11.62%
Jun-19-24 09:23AM	Meridian Small Cap Growth Fund Trimmed Neurogene (NGNE) on Share Price Appreciation (Insider Monkey)
Jun-18-24 09:26AM	Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome (Business Wire) -24.20%
Jun-05-24 07:30AM	Neurogene to Participate in Upcoming Conferences (Business Wire)
Jun-03-24 07:30AM	Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program (Business Wire)
May-10-24 01:54PM	NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire)
May-07-24 06:19AM	Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting (Business Wire)
Apr-22-24 04:36PM	Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting (Business Wire)
Mar-20-24 05:31AM	Neurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
Mar-18-24 04:14PM	Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates (Business Wire) +20.00%
Mar-04-24 07:30AM	Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial (Business Wire) +20.47%
Feb-29-24 07:30AM	Neurogene to Participate in Upcoming Investor Conferences (Business Wire)
Jan-16-24 07:00AM	Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer (Business Wire) +7.27%
Jan-05-24 07:00AM	Neurogene Announces Business Update and 2024 Outlook (Business Wire) +6.50%
Dec-19-23 07:00AM	Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million (Business Wire) +8.17%

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cobb Stuart	Chief Scientific Officer	May 14 '25	Sale	15.15	6,797	103,003	20,794	May 15 04:43 PM
STUART COBB	Officer	May 14 '25	Proposed Sale	15.51	6,797	105,421		May 14 04:29 PM
Cvijic Christine Mikail	President and CFO	Mar 13 '25	Sale	16.94	4,501	76,247	72,343	Mar 17 05:14 PM
Samsara BioCapital GP, LLC	10% Owner	Nov 26 '24	Buy	25.83	48,770	1,259,623	1,717,127	Nov 27 04:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

NGNE

Neurogene Inc

Upgrade your FINVIZ experience